Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Diabetes Care (2010) 33:16079
The GLP-1 analog liraglutide, a modified human GLP-1(737) with a longer half-life 29 , is administered systemically in patients with type II diabetes (commercial name Victoza ) and obesity (commercial name Saxenda )
Additionally, it is essential to notify your healthcare provider if you experience any side effects
Use of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors is on the rise owing, at least in part, to their glycemic benefits, lack of weight gain, and complementary mechanisms of action when used in combination with metformin or other antihyperglycemic medication classes
G., Ho, Y
US$ 21.88
US$ 28.26
US$ 24.89
US$ 28.02
US$ 21.54
US$ 24.33
